The emergence of mephedrone together with other artificial cathinones has presented challenges for lawmakers and regulatory agencies tasked with managing the proliferation of recent psychoactive substances. The dynamic nature of artificial drug creation, coupled with the ability of chemists to modify molecular buildings to evade authorized restrict